Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2023 on February 7, 2024

Conference Call Scheduled for Wednesday, February 7 at 4:30 p.m. Eastern Time SAN DIEGO, Jan. 31, 2024 /PRNewswire/ — Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks


ADVERTISEMENT — Advertise With Biotech Networks